NCT05973604

Prevalence of Primary Aldosteronism in Atrial Fibrillation

Prevalence of Primary Aldosteronism in Patients With Atrial Fibrillation (ERETRIA Trial)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Aristotle University Of Thessaloniki · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

This is an observational prospective cross-sectional study, investigating the prevalence of primary aldosteronism in patients with atrial fibrillation.

Conditions

• Atrial Fibrillation
• Primary Aldosteronism

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Screening and Confirmatory diagnostic test for primary aldosteronism	Screening for primary aldosteronism will be performed with measurement of aldosterone-to-renin ratio after 2 hours of bed rest. Renin measurement will be performed by estimating plasma renin activity. The screening test will be considered positive when the ratio is \>30, accompanied by elevated aldosterone values (\>15 ng/ml). Patients with a positive result will undergo further confirmatory testing with intravenous sodium test (administration 2 liters of normal saline N/S 0.9%, over a period of 4 hours, while the patient is supine. Considered positive if aldosterone levels are \>5mg/dl at the end of the test). Alternative confirmatory methods are captopril test (Administration of 50 mg of captopril. Considered positive when aldosterone levels are \>8.5 mg/dl 2 hours after the intake) or hydrocortisone test (Administration of 0.1mg of hydrocortisone 4 times a day for a period of 4 days. Considered positive if elevated aldosterone levels (\>6ng/dl) are found at the end of the test).

Timeline

• Start date: 2021-09-01
• Primary completion: 2024-09-01
• Completion: 2024-09-01
• First posted: 2023-08-03
• Last updated: 2023-08-03

Locations

1 site across 1 country: Greece